Presbia (PRIVATE.LENS)

Overall impact
B (68)

Commentary

Presbia is a strong overall performer. With a 'B' rating of 67.8 for overall impact (78th percentile compared to all companies), Presbia ranks 43rd out of 103 industry peers, behind MyMD Pharmaceuticals, Alphatec, electroCore and 39 others, and ahead of Waters, Biolase, Biomerica and 57 others. On top material causes for Presbia's industry (Healthcare Equipment), Presbia performs well in Child and Maternal Health (90.0 score), Child and Maternal Health (81.5), Improved Mental Health (89.4) and 3 other causes where it received an 'A' score and performs poorly in Disease Eradication (37.1 score) and Sanitation Access (25.3).
Impact
Cause PRIVATE.LENS
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2008
Employees
20
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Ireland
Share classes
PRIVATE.LENS
Description
Presbia PLC operates as an ophthalmic device company. It develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The company operates in one operating segment, the restoration of clear vision caused by presbyopia. It offers Microlens, which is a disc-shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. It benefits individuals suffering from presbyopia but do not have any other visual disorders. Geographically, all the business is functioned through the region of Ireland, and it also has its business presence across the Netherlands, Germany, Japan, and Canada.
Material causes
Ethos considers the following causes material for Presbia, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.